Investigating how cancer immunotherapy can trigger immune responses in lung cancer
Official title: Tumor-barcoding coupled with high-throughput sequencing for quantitative radiogenomics of the abscopal response in NSCLC
Funded at University of Maryland Baltimore · NIH-11001496 · Data updated 2026-11-12
This study is exploring how treating one tumor can sometimes help fight other tumors in people with non-small cell lung cancer, and it's designed for patients looking for better treatment options that combine immunotherapy and radiation.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Maryland Baltimore NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | January 1, 2023 |
| Project end | December 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $599,214 |
| NIH project number | 5R01CA271540-03 |
| Project ID | NIH-11001496 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who have not responded to standard immunotherapy treatments.
✕Less likely to help
Patients with other types of lung cancer or those who have not been diagnosed with cancer may not benefit from this research.
What this research studies
This research focuses on understanding the abscopal effect, where localized cancer treatment can lead to systemic anti-tumor responses in non-small cell lung cancer (NSCLC). By using advanced techniques like tumor barcoding and high-throughput sequencing, the study aims to create genetically engineered mouse models that can accurately predict how different treatments work together. This approach seeks to improve the effectiveness of immunotherapy combined with radiation therapy, particularly for patients whose tumors do not respond well to current treatments.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment strategies for patients with non-small cell lung cancer, potentially improving their outcomes.
How similar studies have gone: Previous research has shown promise in using similar immunotherapy approaches, but this specific combination and methodology is relatively novel.
Where this research is happening
-
University of Maryland Baltimore
Baltimore, United States Active
Researchers
- Principal investigator: Tran, Phuoc T. — University of Maryland Baltimore
- Study coordinator: Tran, Phuoc T.
Related research
Other NIH-funded projects on the same topics.
-
7-marker protein test to predict NSCLC response to anti-PD-1 therapy
A Johns Hopkins team is testing a 7-marker protein test to help predict which advanced NSCLC patients will respond to anti-PD-1 therapy.
-
Barcoded tumor sequencing to map radiation-triggered immune effects in lung cancer
This project uses barcoded tumor models and sequencing to uncover how adding radiation to immunotherapy might spark whole-body immune attacks against non-small cell lung cancer.
-
Targeting the cancer-friendly secretory system in a common lung cancer cancer subtype
A study tests new ways to block the secretory system inside tumor cells to stop growth and spread in a major subtype of non-small cell lung cancer.
-
Predicting outcomes and side effects in stage III NSCLC with AI-driven imaging
A multimodal AI approach uses chest CT and tissue images to forecast how patients with unresectable stage III NSCLC will respond to durvalumab after chemoradiotherapy and who might develop pneumonitis.
-
ATM kinase as a target to help NSCLC with brain metastases respond to treatment
A study from Yale University tests whether blocking ATM kinase can delay or overcome treatment resistance in people with advanced non-small cell lung cancer that has spread to the brain and other organs.
-
Understanding how cancer-supportive tissue affects resistance to ALK and KRAS therapies
A research team will study how the tumor’s surrounding tissue changes as cancer cells become resistant to ALK and KRAS-targeted treatments, aiming to find better combination strategies for long-lasting remission.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.